by admin | Jan 16, 2026 | News & Opinions
by Charles Bankhead – MedPageToday – Long-term survival in the CARTITUDE-1 trial showed that almost half of patients remained, alive with a median overall survival (OS) of 60.7 months. Almost three-fourths of the survivors remained progression free, and...
by admin | Jan 15, 2026 | News & Opinions
By Julie Grisham – Memorial Sloan Kettering Cancer Center – When it comes to giving immunotherapy to people with the most common form of lymphoma, the time of day may make a difference, according to new research from Memorial Sloan Kettering Cancer Center...
by admin | Jan 14, 2026 | News & Opinions
By Chinese Academy of Sciences – SciTechDaily – A new method for engineering natural killer cells could make cancer immunotherapy more efficient, scalable, and affordable, potentially reshaping how these treatments are produced. Chinese scientists have...
by admin | Jan 13, 2026 | News & Opinions
By Frank Vinluan – MedCity News – A rare but severe stem cell transplant complication that often becomes fatal now has its first FDA-approved treatment, a therapy developed by biotechnology company Omeros. Omeros’s complement system drug Yartemlea is now...
by admin | Jan 12, 2026 | News & Opinions
By Matt Hoffman – CGTlive – As 2025 comes to a close, CGTLive has looked back on some of the most-read and most impactful FDA regulatory decisions and news in the cell and gene therapy space. These approvals and regulatory actions marked major progress for...
